A Phase II, Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of Mycophenolate Mofetil and Rilonacept (Anti-interleukin-1) in Patients With Alcoholic Hepatitis
This is a prospective, randomized trial of two experimental treatments, prednisolone +
mycophenolate mofetil and prednisolone + rilonacept, in comparison with standard of care, in
patients with alcoholic hepatitis. Patients will start therapy with prednisolone. At Day 8
response to prednisolone will be determined using the Lille score. Patients with a Lille
score ≥ 0.45 will be randomized to standard of care (continue prednisolone, stop all therapy
and/or offer palliative care) or to have prednisolone continued and mycophenolate added for
the next three weeks. Patients with a Lille score <0.45 will be randomized to continue
prednisolone alone (standard of care) or to have rilonacept added to their treatment regimen
(experimental group) for the next three weeks. Patients will complete follow-up visits at
Week 12 and Week 24.
A pilot study of a mobile app to collect magnetic resonance imaging information in patients with multiple sclerosis
This pilot study examines the ability of a mobile application (app) to collect data from active tasks (such as questionnaires, 6Mapp™, COGapp™, VISapp™) and clinical magnetic resonance imaging information to analyze the extent to which genetics impact subjects with multiple sclerosis. Recruitment to the study will be done through different sources: patient advocacy groups, social media tools, clinicaltrials.gov, and flyers.
Not yet recruiting | clinical magnetic resonance imaging | Not Multisite
Powered by
SC CTSI